KIAA1217: A Potential Drug Target and Biomarker (G56243)
KIAA1217: A Potential Drug Target and Biomarker
Introduction
KIAA1217 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a key regulator of the cell cycle, and its levels have been linked to the development and progression of many diseases, including cancer. In recent years, the research team has discovered the expression levels of KIAA1217 in a variety of diseases, including cancer, neurological diseases, and metabolic diseases. In addition, KIAA1217 was also found to be associated with several drug targets that have potential implications for the treatment of these diseases.
What does KIAA1217 do?
KIAA1217 is a transcription factor that regulates gene expression during the cell cycle. Studies have shown that KIAA1217 has higher expression levels in cells in the G1 and G2 phases, while lower expression levels in cells in the S and G0 phases. This suggests that KIAA1217 plays different roles in different stages of the cell cycle.
In addition, studies have shown that KIAA1217 is also involved in some important biological processes, including cell proliferation, apoptosis and cell differentiation. For example, studies have shown that KIAA1217 plays an important role in tumorigenesis and cell cycle regulation. In addition, KIAA1217 also interacts with some important proteins, including histones, p21 and p53.
Pharmacological significance of KIAA1217
KIAA1217 is considered a potential drug target due to its role in many diseases. First, studies have shown that activation of KIAA1217 can lead to cell proliferation and apoptosis, therefore, inhibitors of KIAA1217 can inhibit tumor growth. In addition, activation of KIAA1217 may also lead to cell cycle arrest. Therefore, inhibitors of KIAA1217 may also inhibit the proliferation of cancer cells.
Secondly, studies have shown that activation of KIAA1217 is related to the occurrence and development of some diseases. For example, studies have shown that activation of KIAA1217 is associated with neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In addition, activation of KIAA1217 is also associated with liver diseases, such as liver
Protein Name: KIAA1217
Functions: Required for normal development of intervertebral disks
More Common Targets
KIAA1328 | KIAA1522 | KIAA1549 | KIAA1549L | KIAA1586 | KIAA1614 | KIAA1656 | KIAA1671 | KIAA1671-AS1 | KIAA1755 | KIAA1958 | KIAA2012 | KIAA2013 | KIAA2026 | KICS2 | KIDINS220 | KIF11 | KIF12 | KIF13A | KIF13B | KIF14 | KIF15 | KIF16B | KIF17 | KIF18A | KIF18B | KIF19 | KIF1A | KIF1B | KIF1C | KIF20A | KIF20B | KIF21A | KIF21B | KIF22 | KIF23 | KIF23-AS1 | KIF24 | KIF25 | KIF25-AS1 | KIF26A | KIF26B | KIF27 | KIF28P | KIF2A | KIF2B | KIF2C | KIF3A | KIF3B | KIF3C | KIF4A | KIF4B | KIF5A | KIF5B | KIF5C | KIF6 | KIF7 | KIF9 | KIF9-AS1 | KIFAP3 | KIFBP | KIFC1 | KIFC2 | KIFC3 | Killer Cell Immunoglobulin-Like Receptor (KIR) | Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 | KIN | Kinesin-like protein KIF16B (isoform 1) | KIR2DL1 | KIR2DL2 | KIR2DL3 | KIR2DL4 | KIR2DL5A | KIR2DL5B | KIR2DP1 | KIR2DS1 | KIR2DS2 | KIR2DS3 | KIR2DS4 | KIR2DS5 | KIR3DL1 | KIR3DL2 | KIR3DL3 | KIR3DP1 | KIR3DS1 | KIR3DX1 | KIRREL1 | KIRREL1-IT1 | KIRREL2 | KIRREL3 | KIRREL3-AS2 | KIRREL3-AS3 | KISS1 | KISS1R | KIT | KITLG | KIZ | KIZ-AS1 | KL | KLB